Stora Enso Oyj Valuation
Is STERV undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of STERV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: STERV (€9.29) is trading above our estimate of fair value (€7)
Significantly Below Fair Value: STERV is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for STERV?
Key metric: As STERV is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is STERV's PS Ratio? | |
|---|---|
| PS Ratio | 0.8x |
| Sales | €8.90b |
| Market Cap | €7.32b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.2x |
| Enterprise Value/EBITDA | 15.7x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does STERV's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1x | ||
UPM UPM-Kymmene Oyj | 1.3x | 3.8% | €13.5b |
HUH1V Huhtamäki Oyj | 0.9x | 4.3% | €3.6b |
KEMIRA Kemira Oyj | 0.9x | 1.4% | €2.9b |
METSB Metsä Board Oyj | 0.8x | 7.6% | €1.6b |
STERV Stora Enso Oyj | 0.8x | 6.1% | €7.3b |
Price-To-Sales vs Peers: STERV is good value based on its Price-To-Sales Ratio (0.8x) compared to the peer average (1x).
Price to Sales Ratio vs Industry
How does STERV's PS Ratio compare vs other companies in the European Forestry Industry?
| 0 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 0 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Sales vs Industry: STERV is expensive based on its Price-To-Sales Ratio (0.8x) compared to the European Forestry industry average (0.7x).
Price to Sales Ratio vs Fair Ratio
What is STERV's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.8x |
| Fair PS Ratio | 1.7x |
Price-To-Sales vs Fair Ratio: STERV is good value based on its Price-To-Sales Ratio (0.8x) compared to the estimated Fair Price-To-Sales Ratio (1.7x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €9.29 | €13.28 +43.0% | 13.9% | €17.40 | €9.80 | n/a | 15 |
| Nov ’25 | €10.38 | €13.65 +31.5% | 13.2% | €17.40 | €10.00 | n/a | 15 |
| Oct ’25 | €11.45 | €13.89 +21.4% | 14.2% | €16.50 | €10.00 | n/a | 15 |
| Sep ’25 | €11.70 | €13.84 +18.3% | 14.7% | €17.00 | €10.00 | n/a | 16 |
| Aug ’25 | €11.34 | €14.09 +24.3% | 14.3% | €17.00 | €10.30 | n/a | 16 |
| Jul ’25 | €12.89 | €13.95 +8.2% | 15.4% | €17.00 | €9.80 | n/a | 14 |
| Jun ’25 | €13.41 | €13.56 +1.2% | 15.8% | €17.00 | €9.80 | n/a | 14 |
| May ’25 | €12.55 | €13.32 +6.1% | 14.3% | €16.50 | €9.80 | n/a | 14 |
| Apr ’25 | €12.89 | €12.65 -1.8% | 14.7% | €16.00 | €9.60 | n/a | 14 |
| Mar ’25 | €11.79 | €12.53 +6.3% | 12.1% | €14.50 | €9.60 | n/a | 13 |
| Feb ’25 | €11.25 | €12.98 +15.5% | 13.5% | €15.20 | €9.60 | n/a | 13 |
| Jan ’25 | €12.53 | €12.92 +3.1% | 13.3% | €15.50 | €10.00 | n/a | 13 |
| Dec ’24 | €12.00 | €12.84 +7.0% | 13.5% | €15.50 | €10.00 | €9.19 | 13 |
| Nov ’24 | €11.32 | €12.80 +13.1% | 14.3% | €15.50 | €10.00 | €10.38 | 13 |
| Oct ’24 | €11.89 | €12.48 +4.9% | 15.8% | €15.50 | €9.70 | €11.45 | 13 |
| Sep ’24 | €11.86 | €12.69 +7.0% | 16.0% | €15.50 | €9.80 | €11.70 | 14 |
| Aug ’24 | €11.21 | €12.73 +13.5% | 16.4% | €15.90 | €9.80 | €11.34 | 14 |
| Jul ’24 | €10.63 | €13.87 +30.6% | 13.4% | €16.90 | €11.00 | €12.89 | 15 |
| Jun ’24 | €11.97 | €13.80 +15.3% | 13.6% | €16.90 | €11.00 | €13.41 | 14 |
| May ’24 | €11.50 | €13.80 +20.0% | 13.7% | €16.90 | €11.00 | €12.55 | 14 |
| Apr ’24 | €11.98 | €15.44 +28.9% | 9.8% | €18.00 | €13.00 | €12.89 | 13 |
| Mar ’24 | €13.58 | €15.38 +13.3% | 10.7% | €18.00 | €13.00 | €11.79 | 12 |
| Feb ’24 | €13.42 | €15.46 +15.2% | 10.3% | €18.00 | €13.00 | €11.25 | 11 |
| Jan ’24 | €13.15 | €16.15 +22.8% | 13.6% | €21.00 | €14.00 | €12.53 | 11 |
| Dec ’23 | €14.20 | €16.11 +13.5% | 13.0% | €21.00 | €14.00 | €12.00 | 12 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.